Hamad Medical Corporation (HMC) recently organized the International Conference of Hepatocellular Carcinoma in conjunction with the Pan Arab Liver Transplantation Society, International Liver Transplantation Society and International Liver Cancer Association.
The conference, which discussed some 50 research papers on latest developments in the diagnosis and treatment of liver cancer, featured cancer treatment and liver transplantation experts from the UAE, Saudi Arabia, Kuwait, Egypt, Jordan, Iraq, United States, Europe and Japan.
During his opening speech, Dr. Yousef Al-Maslamani, Medical Director of Hamad General Hospital and Director of Qatar Centre for Organ Transplantation, said advanced services in liver cancer treatment and surgery demonstrated how HMC was continuing to provide the safest, most effective and most compassionate care for each and every one of its patients.
Dr. Al-Maslamani noted that transplantation is one of the best treatments for chronic diseases such as liver cancer. He said successful treatment of such diseases also depends on the expertise of highly qualified physicians such as oncologists, radiation therapists, surgery physicians, in addition to nurses and technicians, which he said is contributing to increasing number of transplant operations over the past years.
Dr. Abdullah Al-Ansari, Vice President of Medical, Academic Affairs and Surgical Research Services, and Chairman of Surgery Department at HMC noted that the methods of treatment of liver cancer vary according to the patient's health condition and vulnerability to hepatic fibrosis (overly exuberant wound healing in which excessive connective tissue builds up in the liver). “Qatar has become one of the leading countries in the Arab region in the field of transplantation since the launch of the national program for organ transplantation at HMC in 2011,” he said.